Navigation Links
Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
Date:9/8/2009

ted antibodies in combination with a wide range of anti-cancer agents, including many commonly prescribed chemotherapeutic drugs. This patent was granted to the University of Texas System and is exclusively licensed to Peregrine Pharmaceuticals.

The Phase II trial of bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients has a Simon two-stage design. In the first stage, 15 patients with advanced breast cancer were enrolled and treated with the combination regimen. Nine of the 14 (64%) evaluable patients in this cohort demonstrated an objective tumor response according to RECIST criteria, exceeding the pre-specified primary efficacy endpoint needed to expand enrollment in the trial. An additional 31 patients were then enrolled to achieve the planned study total of 46 patients overall.

"Completion of patient enrollment in our second Phase II breast cancer study marks another milestone for the bavituximab cancer program, with two of our three ongoing Phase II trials now having completed enrollment," said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "We believe the rapid enrollment experienced in all three of these trials is representative of the enthusiasm of our clinical investigators as well as the need for improved cancer therapies. We look forward to reporting further data from these studies in the upcoming months."

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. They may continue to receive bavituximab as monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in India according to International Conference on Harmonization (ICH) and Good Clinical
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Flagship Biosciences LLC, a leading provider of ... medical device industries, has announced a laboratory and office ... consolidated its histology and tissue analysis operations from separate ... north of Denver. The new addresses are: , ... 100, Westminster, CO 80021 , Tissue Image Analysis Lab, ...
(Date:8/27/2014)... 27, 2014 Research and Markets  has ... Ratio Mass Spectrometer Industry Report 2014" report to ... Ratio Mass Spectrometer Industry Report 2014 is a professional ... global isotope ratio mass spectrometer industry. The ... definitions, classifications, applications and industry chain structure. The isotope ...
(Date:8/27/2014)... 27, 2014 Tris Pharma, a specialty pharmaceutical ... announced that it has been selected as an award ... 2014 Awards for Excellence competition in the ... panel of judges from SCORE (Counselors to America,s Small ... be honored at a gala event to be held ...
(Date:8/27/2014)... 27, 2014 BIOEQUA, an innovative line ... use of a handheld spray, has made its EQUA ... , The brand began with an unexpected discovery ... surprised to learn that the application of nanospray technology ... and delivered directly to skin's basal layer. This resulted ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2BIOEQUA'S EQUA ESSENTIAL Product Line Redefines Skin Care & Now Available in America 2
... Inc. (TSX: ONC, NASDAQ: ONCY ) ... combination REOLYSIN(R) and docetaxel clinical trial for patients ... trial is Professor Hardev Pandha of the Royal ... at the Fifth International Meeting on Replicating Oncolytic ...
... marginalized groups including the mentally ill, the disabled ... fare worse than others in the aftermath of ... , Now, a new study by UCLA ... greater terrorism-related fears and make more behavioral changes based ...
... power, and much of that juice comes from fuel cells. ... to find more efficient ways to power them. , In ... metal, is a strong candidate for providing that initial boost ... another popular fuel cell catalyst, platinum, and it,s more abundant. ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting 2Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting 3Disabled and other vulnerable groups more susceptible to terrorism fears 2Brown chemists create more efficient palladium fuel cell catalysts 2
(Date:8/27/2014)... associated with outcomes after the repair of peripheral ... mechanism of injury, nerve injured, injury location, defect ... repair materials. However, despite numerous studies of outcomes ... is no agreement regarding the independent predictors of ... the predictors has not been quantified. A study ...
(Date:8/27/2014)... a dreaded bacterium that can be found in both ... 28 persons in Denmark have been infected with ... have died. , The bacterium is notoriously difficult to ... adapt to changes in its surroundings, says Associate Professor ... from the Department of Biochemistry and Molecular Biology, she ...
(Date:8/26/2014)... University in St. Louis have developed algorithms to identify ... tearing or breaking. The technology, which needs to be ... may help pinpoint minor strains and tiny injuries in ... The research is available online Aug. 27 in the ... publishes research at the nexus of the physical and ...
Breaking Biology News(10 mins):Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3
... of Biologists is pleased to announce BIOLOGY OPEN (BiO), ... research across all aspects of the biological sciences including ... journal aims to provide rapid publication for peer reviewed, ... fields. BIOLOGY OPEN will address some big issues ...
... a big effect on their life. Some people are ... which can be detrimental to their health and wellbeing. ... , A new study led by Dr Kathryn ... York has added important experimental evidence showing that animal ...
... fish, one from a Caribbean island and one from the Yucatan ... known in any organism, according to a new UC Davis study. ... Venezuela -- and they are all pretty much the same, said ... with Peter Wainwright, a professor of evolution and ecology at UC ...
Cached Biology News:Announcing BIOLOGY OPEN from the Company of Biologists 2Animals have personalities, too 2'Explosive' evolution in pupfish 2
Request Info...
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
... Green I nucleic acid gel stain is ... has bright fluorescence when bound to dsDNA and ... detecting dsDNA in gels using laser scanners or ... stain has also found uses in capillary electrophoresis, ...
Synonym: modified Grace's Insect medium...
Biology Products: